Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
May 23, 2024 17:00 ET
|
Tizona Therapeutics Inc
TTX-080 plus EGFR Inhibitor Cetuximab Demonstrated Promising Evidence of Clinical Activity in Patients with Biomarker-Defined Metastatic Colorectal Cancer and Locally Advanced/Metastatic Head and Neck...
Theratechnologies fait une présentation sur le sudocétaxel zendusortide au Congrès 2024 de l’ASCO qui montre des signes d’une efficacité à long terme et un profil d’innocuité gérable chez les patients atteints de tumeurs solides
May 23, 2024 17:00 ET
|
Theratechnologies
L’affiche souligne la stabilisation durable de la maladie après la fin du traitementLes résultats suggèrent un mode d’action multimodal unique qui diffère des autres traitements contre le cancerUne...
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
May 23, 2024 17:00 ET
|
Theratechnologies
Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer therapeuticsFavorable...
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
May 23, 2024 17:00 ET
|
Iovance Biotherapeutics, Inc.
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO Oral Presentation to...
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 23, 2024 17:00 ET
|
Merus N.V.
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster...
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
May 23, 2024 17:00 ET
|
Merus N.V.
- 60% response rate observed among 10 evaluable patients - Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed - ...
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
May 23, 2024 17:00 ET
|
Werewolf Therapeutics, Inc.
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - ...
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
May 23, 2024 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
May 23, 2024 08:00 ET
|
CRISPR Therapeutics AG
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) --...
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 23, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...